BTIG raised the firm’s price target on Natera to $150 from $135 and keeps a Buy rating on the shares with a Top Pick designation. The company unveiled what the firm regards as “groundbreaking and practice-changing data” at the 2024 Congress of the European Society for Medical Oncology, the analyst tells investors in a research note, stating that in the key read out of the GALAXY arm of the prospective CIRCULATE-Japan trial, study investigators reported out strong evidence of the ability for NTRA‘s Signatera MRD test to predict overall survival and for adjuvant chemotherapy benefit in patients with colorectal cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera announces new data from GALAXY arm of ongoing CIRCULATE-Japan trial
- Natera ALTAIR data readout could drive guideline inclusion, says Canaccord
- Election 2024: Where To Put Your Money Ahead of the Vote
- Natera price target raised to $145 from $130 at Canaccord
- Natera price target raised to $132 from $125 at Morgan Stanley